D
Dutch Ophthalmic Research Center
D.O.R.C. enhances global eye surgery and maximises surgeon control by offering innovative quality approaches for eye disorders
About Dutch Ophthalmic Research Center
In 1983, an instrument maker at the Rotterdam Eye Hospital named Ger Vijfvinkel founded the Dutch Ophthalmic Research Center, or DORC. His vision was to create high-quality instruments and equipment for eye surgery. The company started by building a product portfolio through close collaboration with leading surgeons, a practice that would become core to its identity. Based in Zuidland, Netherlands, DORC specialized in developing tools for vitreo-retinal surgery, addressing the delicate procedures involving the retina and the gel-like vitreous humor inside the eye. DORC established itself as a key player by focusing on innovation for surgeons. The company became a leading global supplier of equipment, disposables, and liquids for ophthalmic surgery, exporting its products to over 80 countries. A cornerstone of their offering became the EVA NEXUS platform, a dual-function system for both vitreo-retinal and cataract procedures, allowing surgeons to use a single machine for various surgery types. The company's growth and strong market position attracted investors. After being owned by several private equity firms, DORC was acquired by the French investment firm Eurazeo in 2019. This led to a major turning point in late 2023, when Carl Zeiss Meditec, a German medical technology giant, announced it would acquire DORC from Eurazeo for approximately €985 million. The acquisition, which was completed in April 2024, was a strategic move for Zeiss to enhance its ophthalmology portfolio and strengthen its position in the retinal surgery market.
Source: Dealroom company dataKnowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Dec 2023 | $1.1B | $1.1B | Zeiss | ↗ |
| GROWTH EQUITY VCOther financing | Jul 2020 | $88M | — | Undisclosed | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Dutch Ophthalmic Research Center is 7.8K monthly website visits, up 18.2% over the last three months. Dutch Ophthalmic Research Center's team declined 1.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
- BPBolster Investment Partners
Other known investors3 additional known investors
Eurazeo
Montagu
Zeiss
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Dutch Ophthalmic Research Center on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Dutch Ophthalmic Research Center’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







